Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Rewarding Innovation Was the Primary Goal in 2022 Reform Debate: MHLW Official
January 7, 2022
- MHLW to Reshuffle Organization by Summer to Further Support Drug Development; Economic Affairs Division to Be Renamed
January 7, 2022
- MHLW’s COVID-19 Guide Adds MSD’s Molnupiravir
January 6, 2022
- Japan’s Drug Production Down 1.9% to 9.3 Trillion Yen in 2020: MHLW
January 6, 2022
- Japan Govt to End Observational Avigan Study for COVID-19
January 5, 2022
- MHLW Finalizes Paper on Emergency Approval System, Set to Submit Bill Next Year
December 28, 2021
- 50 Million Yen Earmarked to Support API Stockpiles to Ensure Stable Supplies: MHLW FY2022 Budget
December 28, 2021
- Japan Approves Lenvima/Keytruda Pair, Opdivo Label Expansion
December 27, 2021
- Payer, Healthcare Reps Call for Stable Supply Measures for Achieving New Generic Share Target: Chuikyo
December 27, 2021
- Sakigake Status Dropped for GSK’s Biliary Tract Cancer Drug
December 27, 2021
- Second Case of TTS with Possible Link to AstraZeneca COVID-19 Vaccine Reported in Japan
December 27, 2021
- Japan Does Not Recommend Ronapreve for Omicron Variant
December 27, 2021
- 145 Million Yen Allocated for 3 New Projects to Shake Off Public Distrust in Generics: MHLW FY2022 Budget
December 27, 2021
- Japan Secures 18 Million Extra Doses of Moderna Vaccines
December 27, 2021
- Japan Approves MSD’s Oral COVID-19 Drug Molnupiravir
December 27, 2021
- Regulatory Reform Panel Urges Better Trial Environment, SaMD Review
December 24, 2021
- MHLW to Set Up New Working Group to Discuss Technical Issues in Distribution: Ryukaikon
December 24, 2021
- New Generic Target Enshrined in Govt’s Updated Fiscal Reform Timeline
December 24, 2021
- Japan Panel OKs HPV “Catch-Up” Shots for Females Born in FY1997-FY2005
December 24, 2021
- Ronapreve Given to Nearly 37,000 People in Japan by November, Xevudy to 270: MHLW
December 24, 2021
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…